Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Q1 2026 earnings

Reported May 6, 2026 · After market close

Revenue$36.2MBeat by $4.3M
EPS$0.18Beat by $0.12
Revenue estimate$32.0M
EPS estimate$0.06

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$37.1M
EPS estimate$0.14

Financials

Q1 2026

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$547.19M+35.0%
Enterprise value$452.74M+5.3%
P/E4.4×—
P/S4.5×-5.5×

Profitability

See full
Gross margin86.1%+7.2pp
Net margin101.6%+60.1pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity0×-1.5×
Current ratio4.9×+1.9×

Segments

By product

See full
MIPLYFFA$24.6M+43.9%
OLPRUVA$300.0K+200%

By segment

See full
Reportable Segment$36.2M+77.5%

FAQ

When did Zevra Therapeutics, Inc. report Q1 2026 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q1 2026 earnings on May 6, 2026 after market close.
What were Zevra Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $36.2M and eps of $0.18 for Q1 2026.
Did Zevra Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $32.0M by $4.3M. EPS beat the consensus estimate of $0.06 by $0.12.
How did Zevra Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 77.5% from $20.4M a year earlier.
Where can I find Zevra Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001434647-26-000029) and the 10-Q periodic report (0001434647-26-000031) directly on SEC EDGAR. The filing index links above go to sec.gov.